Table 2 Subject characteristics for the women who were diagnosed with and undergoing chemotherapy treatment for breast cancer (BC).
Characteristics | Frequency (%) |
|---|---|
Cancer stage | |
I | 4 (19) |
II | 9 (43) |
III | 4 (19) |
Not identified/missing | 4 (19) |
Menopause status | |
Post-menopausal | 12 (57) |
Pre-menopausal | 9 (43) |
Chemotherapy drugs | |
Included as part of total treatment regimen | |
Doxorubicin | 8 |
Capecitabine | 1 |
Carboplatin | 10 |
Cyclophosphamide | 10 |
Docetaxel | 12 |
Paclitaxel | 7 |
Chemotherapy treatment combination/sequence | |
Treatment received up to enrollment date | |
Doxorubicin, cyclophosphamide | 2 (10) |
Doxorubicin, cyclophosphamide, paclitaxel | 5 (23) |
Doxorubicin, cyclophosphamide, paclitaxel, capecitabine | 1 (5) |
Docetaxel, carboplatin, trastuzumab, pertuzumab | 8 (38) |
Docetaxel, carboplatin, trastuzumab | 2 (10) |
Docetaxel, cyclophosphamide | 2 (10) |
Paclitaxel | 1 (5) |
Mean time | Days (± SD) |
Average time between most recent treatment and psychological questionnaires | 11.4 (11.3) |
Range of time between most recent treatment and psychological questionnaires | 0–40 |
Average time between most recent treatment and stool samples | 13 (14.4) |
Range of time between most recent treatment and stool samples | 0–42 |
